Marvel Biosciences Corp.
Sign in to search companies, open filing PDFs, fetch uncached SEDAR+ documents, and use the
full company research view.
Transactions 2026-04-27 Financing
Report of exempt distribution (45-106F1).pdf
News 2026-04-23
Marvel Biosciences to Participate and Present at the 2nd Neuroscience Innovation Partnering and Licensing Summit
News release - English.pdf
Transactions 2026-04-17 Financing
MARVEL BIOSCIENCES ANNOUNCES CLOSING OF CONVERTIBLE DEBENTURE OFFERING
News release - English.pdf
News 2026-04-16
Marvel Biosciences Identifies Liquid Formulations for Neurodevelopmental Disorders
News release - English.pdf
Transactions 2026-04-13 Financing
MARVEL BIOSCIENCES ANNOUNCES AN AMENDMENT TO THE CONVERSION PRICE FOR MARVEL'S PROPOSED CONVERTIBLE DEBENTURE OFFERING
News release - English.pdf
Transactions 2026-04-08 Financing
MARVEL BIOSCIENCES ANNOUNCES PROPOSED CONVERTIBLE DEBENTURE OFFERING
News release - English.pdf
Transactions 2026-04-07 Financing
Marvel Biosciences Secures Financial and Strategic Investment with 5 Horizon Ventures
News release - English.pdf
Results 2026-03-31
Interim MD&A - English.pdf
Results 2026-03-31
Interim financial statements/report – English.pdf
Transactions 2026-03-30 Financing
Marvel Biosciences Secures Alberta Innovates Funding to Support the Phase I Testing of MB-204
News release - English.pdf
News 2026-03-25
Marvel Biosciences Selects Novotech as CRO for Its Phase I Clinical Trial of MB-204
News release - English.pdf
News 2026-03-18
Marvel Biosciences Receives Notice of Allowance for US Patent Application Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
News release - English.pdf
News 2026-03-04
Marvel Biosciences Corp. Sponsors Scientific Meeting on Purines
News release - English.pdf
Transactions 2026-02-18 Financing
Marvel Biosciences Secures Funding to Develop Child-Friendly Liquid Formulation for Neurodevelopmental Disorders
News release - English.pdf
News 2026-02-03
Marvel Biosciences Receives Japanese Patent Covering Composition of Matter for Its Lead Therapeutic Candidate MB-204
News release - English.pdf
News 2026-01-20
Other.pdf
Results 2025-12-18 Financials
Interim MD&A - English.pdf
Results 2025-12-18 Financials
Interim financial statements/report – English.pdf
Results 2025-11-28 Financials
Annual MD&A - English.pdf
Results 2025-11-28 Financials
Audited annual financial statements – English.pdf
News 2025-11-10
News release - English.pdf
News 2025-10-03
News release - English.pdf
News 2025-09-18
Letter from successor auditor.pdf
News 2025-09-18
Notice.pdf
News 2025-09-18
Letter from former auditor.pdf
News 2025-08-18
News release - English.pdf
News 2025-08-11
News release - English.pdf
Results 2025-06-17 Financials
Interim MD&A - English.pdf
Results 2025-06-17 Financials
Interim financial statements/report – English.pdf